Double-blind, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day versus a 21-day low-dose oral contraceptive regimen containing 20 μg ethinyl estradiol and 75 μg gestodene

Contraception

Volumn 64, Issue 2, 2001, Pages 99-105

  Endrikat, J ^a   Cronin, M ^a   Gerlinger, C ^a   Ruebig, A ^a   Schmidt, W ^b   Dusterberg B ^a  

^a BAYER PHARMA AG   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

23 day regimen; Cycle control; Ethinyl estradiol; Gestodene; Oral contraceptives

Indexed keywords

ETHINYLESTRADIOL PLUS GESTODENE; LOW DOSE ORAL CONTRACEPTIVE; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESTRADIOL BLOOD LEVEL; FEMALE; HUMAN; MENSTRUAL CYCLE; MULTICENTER STUDY; NORMAL HUMAN; ORAL CONTRACEPTION; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RELIABILITY; SYSTOLIC BLOOD PRESSURE; TABLET; TREATMENT OUTCOME; VAGINA BLEEDING; VASCULAR DISEASE; WEIGHT REDUCTION;

CONTRACEPTIVES, ORAL; DOUBLE-BLIND METHOD; ETHINYL ESTRADIOL; FEMALE; HUMANS; MENSTRUAL CYCLE; NORPREGNENES; PLACEBOS; PREGNANCY; PROSPECTIVE STUDIES; TIME FACTORS; UTERINE HEMORRHAGE;

EID: 0034762669     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(01)00232-3     Document Type: Article

References (10)

1. A three-year clinical investigation into efficacy, cycle control and tolerability of a new low-dose monophasic oral contraceptive containing gestodene
2. A review of cycle control with a low-dose oral contraceptive containing 75 μg gestodene, and 20 μg ethinylestradiol
3. Comparison of efficacy, cycle control and tolerability of two low-dose oral contraceptives in a multicenter clinical study
4. Oral contraceptives and cycle control: A critical review of the literature
5. Latin America experience with two low-dose oral contraceptives containing 30 μg ethinylestradiol/75 μg gestodene and 20 μg ethinylestradiol/150 μg desogestrel
6. A multicenter, uncontrolled clinical investigation of the contraceptive efficacy, cycle control, and safety of a new low dose oral contraceptive containing 20 Ug ethinyl estradiol and 100 Ug levonorgestrel over six treatment cycles
7. Large observational trial of a new low-dose oral contraceptive containing 20 Ug ethinylestradiol and 100 Ug levonorgestrel (Miranova®) in Germany
8. Shorter pill-free interval in combined oral contraceptives decreases follicular development
9. Cycle control, safety and efficacy of a 24-day regimen of gestodene 60 μg/ethinylestradiol 15 μg and a 21-day regimen of desogestrel 150 μg/ethinylestradiol 20 μg
10. The safety and contraceptive efficacy of a 24-day low-dose oral contraceptive regimen containing gestodene 60 μg and ethinylestradiol 15 μg